Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

Benzinga · 2d ago
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.